USPTO Examiner BATES KEENAN ALEXANDER - Art Unit 1631

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19053424CULTURE MEDIUM AND METHOD FOR INDUCING IPSC DIFFERENTIATION TO OBTAIN MACROPHAGES AND USE THEREOFFebruary 2025May 2025Allow301YesNo
18945053COMPOSITIONS FOR REGULATING PRODUCTION OF AN ANTIBODY LIKE PROTEIN AND RIBONUCLEIC ACIDNovember 2024May 2025Allow610NoNo
18745792COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDJune 2024February 2025Allow810YesNo
18644762SYSTEMS, METHODS, AND COMPOSITIONS FOR PRODUCTION OF CELLULAR AGRICULTURE PRODUCTSApril 2024May 2025Allow1221YesNo
18547750METHOD FOR CONSTRUCTING HUMAN PLURIPOTENT STEM CELL-DERIVED LIVER ORGANOID HAVING ENHANCED DRUG METABOLIC POTENTIAL AND LIVER ORGANOID CONSTRUCTED BY SAME METHODOctober 2023September 2024Allow1310YesNo
17749273HUMAN NASOPHARYNGEAL CARCINOMA CELLS DERIVED FROM PATIENT DERIVED XENOGRAFT AND USES THEREOFMay 2022November 2024Abandon3011NoNo
17708911COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASEMarch 2022March 2024Allow2310YesNo
17704947TACI BINDING MOLECULESMarch 2022February 2025Allow3511NoNo
17587552METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLSJanuary 2022April 2025Allow3821YesNo
17547323METHODS OF PRODUCING ADENOVIRUSDecember 2021May 2024Abandon2910NoNo
17617481MYCOPLASMA MEDIA FORMULATIONSDecember 2021June 2025Abandon4201NoNo
17606583A METHOD TO PREVENT THE MYELIN ABNORMALITES ASSOCIATED WITH ARGINASE DEFICIENCYOctober 2021October 2024Allow3600YesNo
17606502TARGET-SPECIFIC CRISPR MUTANTOctober 2021March 2025Allow4010YesNo
17602119DE NOVO DESIGN OF TUNABLE PH-DRIVEN CONFORMATIONAL SWITCHESOctober 2021May 2025Abandon4301NoNo
17599396DIFFERENTIATION INDUCER CONTAINING NUCLEUS PULPOSUS PROGENITOR CELL MASTER REGULATOR TRANSCRIPTION FACTORS, METHOD FOR PRODUCING INDUCED NUCLEUS PULPOSUS PROGENITOR CELLS, AND USE OF INDUCED NUCLEUS PULPOSUS PROGENITOR CELLSSeptember 2021April 2025Abandon4311NoNo
17598845MOTILE CELL SORTING DEVICESeptember 2021February 2025Abandon4101NoNo
17479831CENTRIFUGAL MEMBER AND WASHING METHODSeptember 2021February 2025Abandon4101NoNo
17438840METHODS OF ANTI-TUMOR THERAPYSeptember 2021January 2025Abandon4010NoNo
17425154SYNP35 (PROC8), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLSJuly 2021April 2025Abandon4510NoNo
17422173Targeted In Vivo Genome ModificationJuly 2021June 2025Abandon4720NoNo
17356980METHODS FOR THE PURIFICATION OF VIRAL VECTORSJune 2021August 2024Allow3820YesYes
17348075MULTIFUNCTIONAL POLYMERIC MICROSPHERE/MICROPARTICLE CELL BIOREACTOR SYSTEM AND SORTING PROCESSJune 2021April 2025Abandon4621NoNo
17340044METHOD FOR RESISTING AGING AND ENHANCING STEMNESS CHARACTERISTICS OF HUMAN MESENCHYMAL STEM CELLSJune 2021September 2024Abandon3920NoNo
17295303GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD73May 2021March 2025Abandon4601NoNo
17291204COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITYMay 2021November 2024Abandon4201NoNo
17246558NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSISApril 2021March 2024Allow3411YesNo
17288141AAV TRIPLE-PLASMID SYSTEMApril 2021April 2025Allow4721YesNo
17279878FRATAXIN EXPRESSION CONSTRUCTS HAVING ENGINEERED PROMOTERS AND METHODS OF USE THEREOFMarch 2021August 2024Allow4110YesNo
17277548METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS IN DYNAMIC SUSPENSION CULTUREMarch 2021March 2025Allow4821YesNo
17196408TARGETED MODIFICATION OF RAT GENOMEMarch 2021March 2024Allow3610NoNo
17271635GENERATION OF FUNCTIONAL BETA CELLS FROM HUMAN PLURIPOTENT STEM CELL-DERIVED ENDOCRINE PROGENITORSFebruary 2021May 2025Abandon5020NoNo
17271123FASL IMMUNOMODULATORY GENE THERAPY COMPOSITIONS AND METHODS FOR USEFebruary 2021July 2024Abandon4010NoNo
17160405CELL RECOVERY METHODJanuary 2021December 2024Abandon4720NoNo
17263124HEPATO-BILIARY-PANCREATIC TISSUES AND METHODS OF MAKING SAMEJanuary 2021May 2025Allow5221YesNo
17261928COMBINATION OF A GLYCOSYLATION INHIBITOR WITH ONE CAR CELL THERAPY FOR TREATING CANCERJanuary 2021November 2024Abandon4511NoNo
17260936METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDSJanuary 2021May 2024Abandon4001NoNo
17253742METHOD FOR PREPARING PELLETS OF CHONDROCYTES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS, AND USE THEREOFDecember 2020July 2024Allow4320YesNo
17050403RECOMBINANT IMMUNOGLOBULINS OF A NEW IGG5 CLASS, ENCODED BY THE HUMAN HEAVY CHAIN PSEUDO-GAMMA GENEOctober 2020May 2025Abandon5521YesNo
17041761NANOSTRUCTURED MAGENTIC SCAFFOLD FOR CONTROLLING STEM CELL DIFFERENTIATIONSeptember 2020April 2024Abandon4310NoNo
17041460NUCLEIC ACID MOLECULES AND APPLICATIONS THEREOF IN HUMAN ANTIBODYSeptember 2020August 2024Allow4721YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BATES, KEENAN ALEXANDER.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner BATES, KEENAN ALEXANDER - Prosecution Strategy Guide

Executive Summary

Examiner BATES, KEENAN ALEXANDER works in Art Unit 1631 and has examined 36 patent applications in our dataset. With an allowance rate of 41.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner BATES, KEENAN ALEXANDER's allowance rate of 41.7% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BATES, KEENAN ALEXANDER receive 1.14 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BATES, KEENAN ALEXANDER is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +83.8% benefit to allowance rate for applications examined by BATES, KEENAN ALEXANDER. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.